Catalent, a global provider of oral, injectable and respiratory drug delivery technologies, raised $871 million by offering 42.5 million shares (100% primary) at $20.50, the midpoint of the $19-$22 range. At its offer price, Catalent commands a market cap of $2.5 billion and an EV of $4.4 billion. Catalent will list on the NYSE under the symbol CTLT. Morgan Stanley, J.P. Morgan, BofA Merrill Lynch, Goldman Sachs, Jefferies & Co. and Deutsche Bank all acted as joint bookrunners on the deal.
